Predictive Role of HRV for PONV in Laparoscopic Cholecystectomy
The Predictive Role of Heart Rate Variability in Postoperative Nausea and Vomiting Among Female Patients Undergoing Elective Laparoscopic Cholecystectomy: A Prospective Observational Study
1 other identifier
observational
110
1 country
1
Brief Summary
Postoperative nausea and vomiting (PONV) are among the most common complications following general anesthesia (GA), significantly affecting patient comfort and recovery. Although various risk factors for PONV have been identified-such as female sex, non-smoking status, and history of motion sickness-these predictors are not always sufficient to determine individual risk accurately. Heart rate variability (HRV) reflects autonomic nervous system (ANS) balance and has been proposed as a potential physiological biomarker for predicting PONV. Reduced HRV is associated with increased vagal imbalance, which may contribute to gastrointestinal (GI) dysregulation and PONV. This prospective observational study aims to investigate the predictive value of HRV in estimating the incidence and severity of PONV in female patients undergoing elective laparoscopic cholecystectomy (LC). A total of 110 participants will be enrolled, and preoperative and early postoperative HRV measurements will be obtained using a validated chest-strap heart rate monitor (Polar H10). HRV parameters, including the standard deviation of normal-to-normal intervals (SDNN), the root mean square of successive differences (RMSSD), and the low-frequency/high-frequency (LF/HF) ratio, will be analyzed via the Elite HRV application. Standardized anesthesia, analgesia, and antiemetic protocols will be used for all participants. PONV severity will be assessed over the first 24 hours postoperatively using a 4-point scale. The primary objective is to evaluate whether preoperative HRV can predict PONV occurrence. Secondary outcomes include correlations between HRV parameters and PONV severity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 15, 2025
CompletedFirst Posted
Study publicly available on registry
April 29, 2025
CompletedStudy Start
First participant enrolled
May 2, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 15, 2025
CompletedSeptember 16, 2025
September 1, 2025
5 months
April 15, 2025
September 15, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Association between preoperative HRV and postoperative nausea and vomiting (PONV) within 24 hours
Preoperative HRV parameters (SDNN, RMSSD, LF/HF ratio) measured during a 5-min rest using Polar H10/Elite HRV. PONV assessed every 4 hours for 24 hours post-surgery using a 5-point ordinal scale (0-4). The predictive association between HRV and PONV incidence/severity will be evaluated.
Within 24 hours postoperatively
Secondary Outcomes (2)
Preoperative HRV parameters (SDNN, RMSSD, LF/HF ratio).
Within 24 hours postoperatively
Postoperative HRV parameters (SDNN, RMSSD, LF/HF ratio).
1 hour postoperative (PACU).
Study Arms (2)
1
Patients who develop postoperative nausea and/or vomiting within the first 24 hours after laparoscopic cholecystectomy.
2
Patients who do not experience postoperative nausea or vomiting within the first 24 hours after laparoscopic cholecystectomy.
Eligibility Criteria
Adult female patients aged 18-65 years, scheduled for elective laparoscopic cholecystectomy under general anesthesia at a tertiary care hospital.
You may qualify if:
- Female patients aged 18 to 65 years
- Scheduled for elective laparoscopic cholecystectomy
- American Society of Anesthesiologists (ASA) physical status I
- Body mass index (BMI) \< 35 kg/m²
- Non-smokers
- Able and willing to provide written informed consent
You may not qualify if:
- History of cardiovascular, neurological, or gastrointestinal disease
- Use of medications affecting HRV (e.g., antihypertensives, diuretics, atropine, antidepressants, antipsychotics, steroids)
- Presence of systemic diseases that may affect PONV risk
- Inability to comply with study procedures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Konya City Hospital
Konya, 42090, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor, Department of Anesthesiology and Reanimation
Study Record Dates
First Submitted
April 15, 2025
First Posted
April 29, 2025
Study Start
May 2, 2025
Primary Completion
September 15, 2025
Study Completion
September 15, 2025
Last Updated
September 16, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared due to institutional policies and data privacy concerns.